Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy

Das, S., Vital, E.M., Horton, S., Bryer, D., El-Sherbiny, Y. ORCID: 0000-0003-4791-3475, Rawstron, A.C., Ponchel, F., Emery, P. and Buch, M.H., 2014. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Annals of the Rheumatic Diseases, 73 (5), pp. 909-912. ISSN 0003-4967

Full text not available from this repository.

Item Type:	Journal article
Publication Title:	Annals of the Rheumatic Diseases
Creators:	Das, S., Vital, E.M., Horton, S., Bryer, D., El-Sherbiny, Y., Rawstron, A.C., Ponchel, F., Emery, P. and Buch, M.H.
Publisher:	BMJ
Date:	2014
Volume:	73
Number:	5
ISSN:	0003-4967
Identifiers:	Number Type 10.1136/annrheumdis-2013-204417 DOI 1199943 Other
Divisions:	Schools > School of Science and Technology
Record created by:	Linda Sullivan
Date Added:	14 Oct 2019 14:51
Last Modified:	14 Oct 2019 14:51
URI:	https://irep.ntu.ac.uk/id/eprint/37954

Actions (login required)

Edit View

Views

Downloads